Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB1 day ago · NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time ...
Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease …
WEB2 days ago · Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer's decision is based on the totality of …
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB12 hours ago · FILE PHOTO: Pfizer news conference in Puurs ... Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the ...
Pfizer's Oxbryta exit may hasten trials of rival experimental sickle ...
WEB12 hours ago · Oxbryta was the centerpiece of Pfizer's $5.4 billion buyout of Global Blood Therapeutics in 2022, one of a number of deals bankrolled by the pandemic-era windfall. ... Reuters, the news and media ...
Pfizer pulls sickle cell pill Oxbryta over safety concerns - STAT
WEB1 day ago · Sept. 25, 2024. Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including ...
Pfizer pulls sickle cell disease therapy Oxbryta from markets
WEB1 day ago · The drug was the centerpiece in Pfizer’s $5.4 billion acquisition of Global Blood Therapeutics in 2022 during a post-COVID M&A spree for the drugmaker. At that time, Pfizer said Oxbryta and GBT ...
Pfizer Recalls All of Its Sickle Cell Disease Treatment Over Safety ...
WEB13 hours ago · Key Takeaways. Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. The drug maker said the benefits of Oxbryta no longer outweigh the risks ...
Pfizer withdraws sickle cell disease treatment from all markets
WEB1 day ago · U.S. drugmaker Pfizer said on Wednesday it is withdrawing its sickle cell disease therapy Oxbryta in all markets where it is approved and discontinuing all studies and access programs related to ...
Pfizer voluntarily withdraws all lots of sickle cell disease treatment ...
WEBWalton Oaks, 25th September 2024 - Pfizer Inc announced today that it is voluntarily withdrawing all lots of OXBRYTA® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide.
Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide …
WEB2 days ago · Pfizer PFE -1.93% said it is voluntarily withdrawing all lots of its sickle cell drug Oxbryta in all markets where it is approved, two years after acquiring its parent company Global Blood ...
- Some results have been removed
Skip to content